Table 1 Mean body weight of mice bearing Calu-6 tumours and treated with vehicle, CDDP at 5 mg kg–1, GS-168AT2 at 15 mg kg–1, and combined GS 168A-T2 at 15.0 mg kg–1 and CDDP at 5 mg kg–1

From: A truncated form of CD9-partner 1 (CD9P-1), GS-168AT2, potently inhibits in vivo tumour-induced angiogenesis and tumour growth

 

Day post-treatment

Treatment

Start of treatment

Day 4

Day 8

Day 12

Day 16

Vehicle

22.35±1.17 g

24.08±1.23 g

24.17±1.17 g

23.59±1.14 g

24.40±1.19 g

CDDP

21.40±0.85 g

22.19±1.04 g

21.06±1.41 g

19.46±1.49 g

18.69±1.97 g

GS-168A-T2

21.74±0.89 g

22.78±0.99 g

23.28±0.90 g

22.90±0.59 g

24.20±1.37 g

GS-168A-T2/CDDP

20.74±1.41 g

21.29±0.59 g

20.13±0.78 g

19.76±1.16 g

18.39±0.74 g

  1. Abbreviation: CDDP=cis-diammine platinium II dichloride.
  2. Results were expressed as mean±s.e. (n=5).
Back to article page